Kite Pharma
KITE
KITE was delisted on the 2nd of October, 2017.
62 hedge funds and large institutions have $273M invested in Kite Pharma in 2014 Q3 according to their latest regulatory filings, with 60 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.
6,315% more capital inflows, than outflows
Capital inflows: $236M | Capital outflows: $3.68M
1,900% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 3
1,140% more funds holding
Funds holding: 5 → 62 (+57)
24.57% more ownership
Funds ownership: 0.63% → 25.2% (+25%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$59.1M |
| 2 |
Deerfield Management
New York
|
+$25M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$24.5M |
| 4 |
JP Morgan Chase
New York
|
+$18.6M |
| 5 |
Soros Fund Management
New York
|
+$16.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.82M |
| 2 |
Emerald Advisers
Leola,
Pennsylvania
|
-$1.08M |
| 3 |
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$513K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$269K |
KITE Hedge Fund Activity: Q3 2014 in Review
62 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Kite Pharma (KITE) for Q3 2014, worth a combined $273M — up 3,812% from $6.98M a quarter earlier.
Buyers outnumbered sellers: 60 funds opened new KITE positions and 3 closed out — a net gain of 57 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Capital Research Global Investors, opening a new position worth an estimated $59.1M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $1.82M sold.
- 62 institutional investors held Kite Pharma (KITE) as of Q3 2014, up from 5 in Q2 2014.
- Funds reported $273M of Kite Pharma stock for Q3 2014, up 3,812% quarter-over-quarter.
- 60 funds opened new Kite Pharma positions in Q3 2014 and 3 closed out, a net change of +57 holders.
- The largest Kite Pharma buyer in Q3 2014 was Capital Research Global Investors, an estimated $59.1M added.
- The largest Kite Pharma seller in Q3 2014 was Alyeska Investment Group, an estimated $1.82M sold.
Based on aggregated 13F filings for Q3 2014.